Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide
Authors:
- on behalf of the Pediatric Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell TransplantationOTon behalf of the Pediatric Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
- Nao YoshidaNYNao Yoshida
- Hiromasa YabeHYHiromasa Yabe
- Ryoji KobayashiRKRyoji Kobayashi
- Miharu YabeMYMiharu Yabe
- Hiroshi KawaguchiHKHiroshi Kawaguchi
- 23 May 2020
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (7) , 1272-1281
Abstract
Fludarabine/cyclophosphamide-based conditioning regimens are standard in bone marrow transplantation (BMT) for acquired bone marrow failure in children, however, graft failure may occur. Using the data from a nationwide transplantation registry, we compared the outcomes of children aged n = 71) or fludarabine/cyclophosphamide (n = 296) between 2000 and 2016. The fludarabine/melphalan regimen provided excellent outcomes, with 3-year overall survival and failure-free survival rates of 98% and 97%, respectively. The 83% 3-year failure-free survival in the fludarabine/cyclophosphamide group was significantly inferior (P = 0.002), whereas the overall survival did not differ between the two groups. Late graft failure was the most common cause of treatment failure in the fludarabine/cyclophosphamide group, which experienced a significantly higher incidence of late graft failure than the fludarabine/melphalan group (11% vs. 3%; P = 0.035). Multivariate analyses showed that the fludarabine/melphalan regimen was associated with a better failure-free survival (hazard ratio [HR] 0.12; P = 0.005) and lower risk of late graft failure (HR 0.16; P = 0.037). Fludarabine/melphalan-based conditioning regimen can be a promising option for children with acquired bone marrow failure receiving BMT.Keywords
This publication has 39 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppressionBone Marrow Transplantation, 2012
- Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemiaBlood, 2011
- Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failureClinical Transplantation, 2010
- Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working partyHaematologica, 2010
- Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemiaBone Marrow Transplantation, 2010
- Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhoodBone Marrow Transplantation, 2007
- Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP systemInternational Journal of Hematology, 2007
- Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescenceBone Marrow Transplantation, 2007
- Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia Following Nonmyeloablative Conditioning Using 200-cGy Total Body Irradiation and FludarabineTransplantation and Cellular Therapy, 2006